Merck & Company Inc (MRK)vsProthena Corporation plc (PRTA)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
PRTA
Prothena Corporation plc
$8.79
-4.97%
HEALTHCARE · Cap: $443.43M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 113411% more annual revenue ($65.77B vs $57.94M). MRK leads profitability with a 13.6% profit margin vs -260.9%. PRTA appears more attractively valued with a PEG of 0.80. PRTA earns a higher WallStSmart Score of 58/100 (C).
MRK
Hold50
out of 100
Grade: D+
PRTA
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for PRTA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 50.5%
Revenue surging 1706.0% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -48.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PRTA
The strongest argument for PRTA centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1706.0% demonstrates continued momentum. PEG of 0.80 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PRTA
The primary concerns for PRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while PRTA is a hypergrowth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
PRTA is growing revenue faster at 1706.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
PRTA scores higher overall (58/100 vs 50/100) and 1706.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Prothena Corporation plc
HEALTHCARE · BIOTECHNOLOGY · USA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?